| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
153,922,000 |
| Market
Cap: |
6.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$36.9 - $39.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
40,000 |
561,286 |
| Total Sell Value |
$0 |
$0 |
$1,546,400 |
$15,378,126 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
2 |
30 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sblendorio Glenn |
CEO |
• • – |
2022-12-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,750 |
203,987 |
|
- |
|
| Carroll David Francis |
CFO |
• – – |
2022-12-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
50,998 |
|
- |
|
| Westby Keith |
SVP & COO |
• – – |
2022-12-02 |
4 |
OE |
$10.03 |
$52,146 |
D/D |
5,199 |
64,958 |
|
- |
|
| Westby Keith |
SVP & COO |
• – – |
2022-12-01 |
4 |
AS |
$22.96 |
$230,289 |
D/D |
(10,030) |
59,759 |
|
26% |
|
| Dugel Pravin |
President |
• – – |
2022-11-17 |
4 |
OE |
$10.03 |
$84,994 |
D/D |
8,474 |
122,473 |
|
- |
|
| Sblendorio Glenn |
CEO |
• • – |
2022-11-02 |
4 |
AS |
$23.01 |
$1,150,500 |
D/D |
(50,000) |
179,689 |
|
5% |
|
| Westby Keith |
SVP & COO |
• – – |
2022-11-01 |
4 |
AS |
$23.92 |
$1,744,151 |
D/D |
(72,916) |
69,128 |
|
1% |
|
| Westby Keith |
SVP & COO |
• – – |
2022-11-01 |
4 |
OE |
$1.45 |
$62,228 |
D/D |
42,916 |
142,044 |
|
- |
|
| Simms Christopher Paul |
SVP, Chief Commercial Officer |
• – – |
2022-08-03 |
4 |
S |
$11.25 |
$138,060 |
D/D |
(12,272) |
28,547 |
|
-95% |
|
| Simms Christopher Paul |
SVP, Chief Commercial Officer |
• – – |
2022-08-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,750 |
40,819 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2022-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
17,500 |
|
- |
|
| Gibney Anthony S |
EVP, Chief Business Officer |
• – – |
2022-07-05 |
4 |
S |
$9.41 |
$73,313 |
D/D |
(7,791) |
10,959 |
|
-84% |
|
| Gibney Anthony S |
EVP, Chief Business Officer |
• – – |
2022-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,750 |
18,750 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2022-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
12,500 |
|
- |
|
| Graves Adrienne L |
Director |
– • – |
2022-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Bolte Axel |
Director |
– • – |
2022-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Roberts Calvin W. |
Director |
– • – |
2022-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Henderson Jane |
Director |
– • – |
2022-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Dugel Pravin |
President |
• – – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,313 |
113,999 |
|
- |
|
| Westby Keith |
SVP & COO |
• – – |
2022-04-18 |
4 |
AS |
$16.63 |
$166,300 |
D/D |
(10,000) |
99,128 |
|
-41% |
|
| Westby Keith |
SVP & COO |
• – – |
2022-04-05 |
4 |
AS |
$19.02 |
$176,808 |
D/D |
(9,298) |
109,128 |
|
-26% |
|
| Westby Keith |
SVP & COO |
• – – |
2022-04-05 |
4 |
OE |
$1.45 |
$13,482 |
D/D |
9,298 |
118,426 |
|
- |
|
| Carroll David Francis |
CFO |
• – – |
2022-04-05 |
4 |
AS |
$19.01 |
$89,043 |
D/D |
(4,684) |
40,166 |
|
-26% |
|
| Carroll David Francis |
CFO |
• – – |
2022-04-05 |
4 |
OE |
$1.45 |
$6,792 |
D/D |
4,684 |
44,850 |
|
- |
|
| Westby Keith |
SVP & COO |
• – – |
2022-04-04 |
4 |
AS |
$19.00 |
$393,346 |
D/D |
(20,702) |
109,128 |
|
-29% |
|
468 Records found
|
|
Page 4 of 19 |
|
|
